High CD4+ T cell density is associated with poor prognosis in patients with non-muscle-invasive bladder cancer

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 9, 2015, Pages 11510-11516

  Zhang, Qinglei ^a,b   Hao, Chongli ^b   Cheng, Guangzhou ^b   Wang, Lei ^b   Wang, Xiang ^b   Li, Chang ^b   Qiu, Juhui ^a   Ding, Kejia ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b TENGZHOU CENTRAL PEOPLE S HOSPITAL   (China)

Author keywords

CD4; non muscle invasive bladder cancers (NMIBC); prognosis; T cells

Indexed keywords

TUMOR MARKER;

ADULT; AGED; BLADDER TUMOR; CD4+ T LYMPHOCYTE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TRANSITIONAL CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, TRANSITIONAL CELL; CD4-POSITIVE T-LYMPHOCYTES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 85013127890     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Rouprêt M; European Association of Urology. Eau guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013. Eur Urol 2013; 64: 639-653.
2. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED. Maintenance bacillus calmette-guerin immunotherapy for recurrent ta, t1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized southwest oncology group study. J Urol 2000; 163: 1124-1129.
3. Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K, Mason MD. A systematic review of intravesical bacillus calmette-guerin plus transurethral resection vs transurethral resection alone in ta and t1 bladder cancer. BJU Int 2001; 88: 209-216.
4. Gontero P, Bohle A, Malmstrom PU, O'Donnell MA, Oderda M, Sylvester R, Witjes F. The role of bacillus calmette-guerin in the treatment of non-muscle-invasive bladder cancer. Eur Urol 2010; 57: 410-429.
5. Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of bcg therapy for bladder cancer--a current perspective. Nat Rev Urol 2014; 11: 153-162.
6. Finn OJ. Cancer immunology. N Engl J Med 2008; 358: 2704-2715.
7. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117: 1167-1174.
8. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer 2012; 12: 298-306.
9. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, Sato E. Cd8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 2007; 104: 3967-3972.
10. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K. Intraepithelial cd8+ tumor-infiltrating lymphocytes and a high cd8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 18538-18543.
11. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H, Ohtani H. Proliferative activity of intratumoral cd8(+) t-lymphocytes as a prognostic factor in human renal cell carcinoma: Clinicopathologic demonstration of antitumor immunity. Cancer Res 2001; 61: 5132-5136.
12. Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudoh S, Ochiai A. Predominant infiltration of macrophages and cd8(+) t cells in cancer nests is a significant predictor of survival in stage iv nonsmall cell lung cancer. Cancer 2008; 113: 1387-1395.
13. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964.
14. Disis ML, Bernhard H, Jaffee EM. Use of tumour-responsive t cells as cancer treatment. Lancet 2009; 373: 673-683.
15. Corthay A, Skovseth DK, Lundin KU, Røsjø E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B. Primary antitumor immune response mediated by cd4+ t cells. Immunity 2005; 22: 371-383.
16. Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O, Matzinger P. Cd4 cells can be more efficient at tumor rejection than cd8 cells. Blood 2007; 109: 5346-5354.
17. Bromwich EJ, McArdle PA, Canna K, McMillan DC, McNicol AM, Brown M, Aitchison M. The relationship between t-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer 2003; 89: 1906-1908.
18. Peguillet I, Milder M, Louis D, Vincent-Salomon A, Dorval T, Piperno-Neumann S, Scholl SM, Lantz O. High numbers of differentiated effector cd4 t cells are found in cancer patients and correlate with clinical response after neo-adjuvant therapy of breast cancer. Cancer Res 2014; 74: 2204-2216.
19. Zhang Q, Jia Q, Deng T, Song B, Li L. Heterogeneous expansion of CD4+ tumor-infiltrating t-lymphocytes in clear cell renal cell carcinomas. Biochem Biophys Res Commun 2015; 458: 70-76.
20. Wang B, Shaoxu W, Zeng H, Liu Z, Dong W, He W, Chen X, Dong X, Zheng L, Lin T, Huang J. CD103 tumor-infiltrating lymphocytes predict a favorable prognosis in urothelial cell carcinoma of the bladder. J Urol 2015; 194: 556-562.
21. Sylvester RJ. How well can you actually predict which non-muscle-invasive bladder cancer patients will progress? Eur Urol 2011; 60: 431-433, discussion 433-434
22. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374: 239-249.
23. Zuiverloon TC, Nieuweboer AJ, Vekony H, Kirkels WJ, Bangma CH, Zwarthoff EC. Markers predicting response to bacillus calmette-guerin immunotherapy in high-risk bladder cancer patients: A systematic review. Eur Urol 2012; 61: 128-145.
24. Zou W. Regulatory t cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
25. Wilke CM, Kryczek I, Wei S, Zhao E, Wu K, Wang G, Zou W. Th17 cells in cancer: Help or hindrance? Carcinogenesis 2011; 32: 643-649.
26. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B,Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory t cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949.
27. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH. Quantification of regulatory t cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24: 5373-5380.
28. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY. Intratumoral balance of regulatory and cytotoxic t cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007; 25: 2586-2593.
29. Nakayamada S, Takahashi H, Kanno Y, O'Shea JJ. Helper t cell diversity and plasticity. Curr Opin Immunol 2012; 24: 297-302.